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Abstract
Background: Emergence of drug-resistant strains of influenza viruses, including avian H5N1 with pandemic potential, 
1918 and 2009 A/H1N1 pandemic viruses to currently used antiviral agents, neuraminidase inhibitors and M2 Ion 
channel blockers, underscores the importance of developing novel antiviral strategies. Activation of innate immune 
pathogen sensor Retinoic Acid Inducible Gene-I (RIG-I) has recently been shown to induce antiviral state.
Results: In the present investigation, using real time RT-PCR, immunofluorescence, immunoblot, and plaque assay we 
show that 5'PPP-containing single stranded RNA (5'PPP-RNA), a ligand for the intracytoplasmic RNA sensor, RIG-I can be 
used as a prophylactic agent against known drug-resistant avian H5N1 and pandemic influenza viruses. 5'PPP-RNA 
treatment of human lung epithelial cells inhibited replication of drug-resistant avian H5N1 as well as 1918 and 2009 
pandemic influenza viruses in a RIG-I and type 1 interferon dependant manner. Additionally, 5'PPP-RNA treatment also 
inhibited 2009 H1N1 viral replication in vivo in mice.
Conclusions: Our findings suggest that 5'PPP-RNA mediated activation of RIG-I can suppress replication of influenza 
viruses irrespective of their genetic make-up, pathogenicity, and drug-sensitivity status.
Background
Annual influenza epidemics caused by influenza A and B
viruses result in three to five million cases of severe ill-
ness with about 250,000 to 500,000 deaths globally every
year. In the United States, complications from influenza
infections result in approximately 250,000 hospitaliza-
tions and 36,000 deaths in an average year, with majority
of the fatalities occurring among the elderly population
[1]. Influenza A viruses are further sub typed based on
hemagglutinin (HA) and neuraminidase (NA) proteins
present on the virion envelope and there are 16 HA and 9
NA types known among influenza A viruses [2,3]. Fre-
quent minor genetic changes, known as antigenic drift
and the emergence of influenza A viruses with novel NA
and/or HA subtypes, known as antigenic shift result in
epidemics and pandemics respectively. In the 20th cen-
tury, only viruses of the H1, H2 or H3 and N1 or N2 sub-
types have caused sustained epidemics in humans.
However, other subtypes namely H7, H9, and H5 which
primarily cause infections and death among avian species
have crossed the species barrier and caused mild to
severe or fatal disease in humans [4]. Since 2003, highly
pathogenic avian influenza (HPAI) H5N1 viruses have
expanded their geographical distribution and are cur-
rently endemic in domestic poultry and wild birds in
approximately 60 countries on three continents [5]. As of
May 61, 2010, 498 human cases in 15 countries with a
60% mortality rate have been reported [6]. Consequently,
these viruses have the potential to cause a pandemic, if
they acquire the ability for sustained transmission among
humans [7,8]. In fact we are in the midst of a pandemic as
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a result of sustained human-to-human transmission by a
novel H1N1 virus containing the gene segments from
avian, human, and swine influenza viruses to which peo-
ple lack immunity [9-11].
Vaccination is the primary strategy for reducing the
morbidity and mortality associated with human influenza
[12-15]. However, the population at risk such as elderly,
pediatric, transplant recipients, and others who are
immunocompromised with either primary or secondary
immunodeficiency disorders remain vulnerable despite
vaccination as in case of avian influenza viral infection
and children, adolescents, pregnant women, and those
with underlying medical conditions as in case of 2009
H1N1 pandemic influenza virus infection [16]. Therefore,
the use of antiviral drugs is a crucial public health coun-
termeasure for preventing and treating influenza, partic-
ularly in circumstances of increased incidence influenza
infections when there is a vaccine mismatch or shortage,
when vaccine usage is limited or non-existent, or when
there is no effective vaccine available globally in the mar-
ket as in the case of H5N1 virus infections. Currently, two
classes of antiviral drugs are available to treat influenza
infections: the M2 ion-channel blockers amantadine and
rimantadine and the NA inhibitors oseltamivir and zana-
mivir [17-20]. However, the emergence of human sea-
sonal, highly virulent H5N1 influenza viruses as well as
2009 H1N1 pandemic influenza viruses that are resistant
to one or both the classes of drugs underscores the need
for development of new generation drugs as well as other
novel preventive and therapeutic strategies [13,21-28].
The immune system has evolved to recognize and elim-
inate pathogens. A number of pathogen recognition
receptor (PRRs) families are involved in pathogen sensing
and can be present in the host as soluble molecules in tis-
sue fluids and serum or as molecules on cell membranes,
localized in various cellular compartments, or in the
cytosol [29-31]. Recognition of pathogen-associated
molecular patterns (PAMPs) by PRRs results in rapid
induction of innate immune responses that include pro-
duction of antiviral cytokines such as the type I interfer-
ons (IFN-I) as well as proinflammatory cytokines
responsible for impairment of viral replication and induc-
tion of adaptive immune responses [32]. The presence of
viral RNA or DNA in cytosol is detected by retinoic acid
inducible gene-I (RIG-I) and melanoma differentiation-
associated gene 5 (MDA-5), DNA-dependent activator of
IFN-regulator factors (DAI) or absent in melanoma 2
(AIM2) [33-36]. Several human viruses, including hepati-
tis C (HCV), vaccinia, Ebola, and influenza have evolved
strategies to target and inhibit distinct steps in the early
signaling events that lead to IFN-I induction, indicating
the importance of IFN-I in the host's antiviral response
[37-40]. In case of influenza viruses, we and others have
shown that nonstructural protein 1 (NS1) inhibits the
function of the RIG-I [41-44]. RIG-I is critical for the
induction of an antiviral innate immune response against
influenza virus and its C-terminal helicase domain con-
tains the characteristic amino acid signature motif of
many RNA binding proteins [45]. The interaction of C-
terminal domain with viral RNA either short double
stranded RNA or 5'PPP-ssRNA with a panhandle struc-
ture facilitates its interaction with IPS-1 (interferon-β
promoter stimulator 1) via its N-terminal CARD (cas-
pase-recruitment domain) [42,46-48]. Recent reports
suggest various ligands for RIG-I including ssRNA and
dsRNA that may require specific sequences or may not
require a triphosphate on their 5'-termini [42,46-53].
Despite the various reports that describe ligands and
mechanisms of RIG-I mediated antiviral response there is
no report that suggests that RIG-I activation can inhibit
replication of influenza viruses irrespective of their
genetic makeup, pathogenecity and drug-resistant status.
In the present study, we investigated whether the evolu-
tionarily conserved antiviral strategies such as the stimu-
lation of RIG-I with 5'PPP-RNA inhibit the replication of
these influenza viruses.
Results
5'PPP-RNA inhibits the replication of 1918 pandemic virus 
as well as both wild-type and drug-resistant H5N1
The 1918 pandemic resulted in 20-50 million deaths
worldwide. To test if the activation of RIG-I with 5'PPP-
RNA could suppress the replication of the reconstructed
1918 virus, we treated A549 cells with 5'PPP-RNA or
CIAP-RNA for 24 hr, and then infected them with 1918
virus at an MOI of 0.01. Supernatants were collected 24
hr post-infection and assayed for viral titer. Figure 1A(i)
indicates that 5'PPP-RNA was able to inhibit 1918 virus
replication by ~99% compared with control or CIAP-
RNA treated cells. Similar inhibitory effect was observed
in experiments where 0.1 MOI was used for infection
(data not shown).
Next we evaluated the prophylactic antiviral potential
of 5'PPP-RNA against avian influenza H5N1 viruses with
pandemic potential. A549 cells were transfected with
5'PPP-RNA or CIAP-RNA for 0, 24 or 48 hr, and infected
with A/Vietnam/1203, an H5N1virus. Viral titers were
determined 24 hr post-infection. As shown in Figure
1A(ii), A549 cells treated with 5'PPP-RNA showed antivi-
ral effect after 24 hr of transfection. This effect was not
seen in control or in CIAP-RNA transfected A549 cells.
This inhibitory effect persisted even after 72 hr (data not
shown) suggesting a sustained antiviral effect of 5'PPP-
RNA.
Stockpiling of the antiviral drug, oseltamivir is one
strategy for pandemic preparedness, but the emergence
of oseltamivir-resistant H5N1 viruses would seriously
impede these efforts. Hence, we also tested the ability ofRanjan et al. Virology Journal 2010, 7:102
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5'PPP-RNA to inhibit the replication of drug-resistant A/
Vietnam/1203/2004 viruses that include zanamivir- and
oseltamivir-sensitive and adamantanes-resistant and ada-
mantanes- and oseltamivir-resistant virus variants, A/
VN/30408/2005 (H274Y) and A/VN/HN/30408/2005
(N294S). As shown in Figure 1B(i-iii), 5'PPP-RNA trans-
fection in A549 cells significantly reduced the replication
of all the three drug-resistant H5N1 viruses. A549 cells
treated with CIAP-RNA did not have any impact on viral
replication and viral titers were comparable to control.
We also used NHBE cells in our studies with H5N1 infec-
tion, and similar antiviral effects of 5'PPP-RNA were
observed (data not shown). Seasonal drug-resistant
H1N1 and H3N2 and their wild-type counter parts were
chosen to measure the efficacy of 5'PPP-RNA treatment
on viral replication. Influenza viruses of different HA and
NA and members of the same subtype have different rep-
lication efficiencies. The replication efficiencies of these
viruses were well characterized in MDCK cells. As
expected, 5'PPP-RNA treatment of A549 cells inhibited
the replication of wild-type and drug-resistant human
seasonal H1N1, H3N2 and B viruses (Additional file 1,
Figure S1). In all cases, activation of RIG-I pathway by
5'PPP-RNA transfection inhibited viral replication by 1.5
to 3 logs. Furthermore, we investigated if the viruses that
grew in the presence of 5'PPP-RNA treatment were
escape mutants that developed resistance to type I inter-
feron. As shown in Additional file 2, Figure S2, the viruses
that grew in the presence of 5'PPP-RNA are still suscepti-
ble to 5'PPP-RNA treatment when tested subsequently.
5'PPP-RNA inhibits 2009 pandemic H1N1 viruses both in 
vitro and in vivo
Global spread of novel 2009 A/H1N1 influenza viruses
containing a constellation of genes from avian, human,
Figure 1 5'PPP-RNA suprresses the replication 1918 virus as well as wild-type and drug-resistant H5N1 viruses. (A) A549 (1 × 106 cells/well) in 
a 6-well tissue culture plate were mock-transfected (control) or transfected with 2 μg of 5'PPP-RNA or CIAP-RNA using lipofectamine 2000 and 24 hr 
later were infected with (i) 1918 pandemic virus (0.01 MOI). (ii), Transfected A549 cells were also infected with wild-type H5N1 (0.1 MOI) following 0, 
24 and 48 hr of transfection. B. Mock, 5'PPP-RNA or CIAP-RNA transfected A549 cells were infected with drug-resistant H5N1 viruses A/VN/1203/2004 
(i), A/VN/30408/2004 H274Y(ii) and A/VN/30408/2004 N294S (iii) 24 hr post transfection. Supernatants collected after 24 hr of infection were assayed 
for viral titers and results shown are mean ± SD of three independent experiments and are expressed as viral titer (pfu/ml).
(A)
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and swine in relatively short period of time is causing
severe disease and fatal outcomes in high-risk popula-
tions. It was clear that vaccine was not available and in
sufficient quantities for use in the first wave of a pan-
demic leading to the reliance on the prophylactic and
therapeutic use of effective antiviral drugs. However,
emergence of oseltamivir-resistant novel 2009 A/H1N1
virus strains underscores the fragility of the public health
strategy to control pandemic [27]. Hence, we tested the
ability of 5'PPP-RNA to inhibit novel 2009 A/H1N1 virus.
As shown in Figure 2A, 5'PPP-RNA transfected A549
cells significantly inhibited A/California/08/09 replica-
tion. Control or CIAP-RNA did not show this suppres-
sion effect. To investigate if in vivo administration of
5'PPP-RNA will reduce viral titers, we delivered 5'PPP-
RNA or PBS formulated in in vivojet-PEI daily for four
days and infected mice on day 1 with A/Mexico/4482/09.
Daily administration of 5'PPP-RNA alone had no side
effects on body weight gain and activity (data not shown).
On day 4 post-challenge, lungs from all animals were col-
lected to determine viral titers. Control group had signifi-
cantly higher viral load in lungs when compared to those
that received 5'PPP-RNA (Figure 2B). The viral titers
from the 5'PPP-RNA group ranged from 40 through106
pfu/ml. Two animals showed viral titers of 40 and 50 and
others showed 3 × 105 to 1 × 106 pfu/ml. These data sug-
gest that 5'PPP-RNA treatment inhibited viral replica-
tion.
5'PPP-RNA induced upregulation of IFNβ and RIG-I
Antiviral effect in response to 5'PPP-RNA has been
shown to be associated with induced RIG-I expression
and subsequent type I interferon production. Therefore,
we investigated the ability of in vitro transcribed 5'PPP-
RNA to induce IFNβ and RIG-I in A549 cells in our
experimental model by real-time RT-PCR. As shown in
Figure 3A(i&ii), transfection of A549 cells with 5'PPP-
RNA resulted in an approximately 200-fold increase in
IFNβ mRNA and ~80-fold increase in RIG-I mRNA
expression level in 24 hr. No induction was observed for
RIG-I or IFNβ level in mock-transfected or A549 cells
transfected with CIAP-RNA or with -OH-RNA. Time-
kinetics studies of RIG-I protein expression as shown in
Figure 3B(i) suggest that 5'PPP-RNA mediated RIG-I
induction was detectable by 6 hr, peaked at 8 hr, and was
present even after 48 hr although we observed a decline
after 72 hr of treatment (data not shown). Similar kinetics
were observed for IFNβ expression by real-time RT-PCR
(data not shown). Figure 3B(ii) demonstrates the specific
effect of 5'PPP-RNA on RIG-I expression at the protein
level in A549 cells that is consistent with real time RT-
PCR data [Figure 3A(ii)]. A similar pattern of RIG-I
induction by 5'PPP-RNA was observed in NHBE cells
(data not shown). We also investigated 5'PPP-RNA
induced RIG-I expression in A549 cells by immunostain-
ing [Figure 3B(iii)]. A549 cells treated with 5'PPP-RNA
showed increased cytosolic expression of RIG-I. Mock or
CIAP-RNA transfected cells did not show detectable lev-
els RIG-I. These experiments were also carried out in
NHBE cells and similar effects of 5'PPP-RNA was
observed (data not shown).
Activation of the innate immune system is critical for
the induction and maintenance of host antiviral defenses.
However, viruses also have evolved mechanism(s) that
circumvent host immune responses. Several studies,
including our own have shown independently that non-
structural protein (NS1) of influenza A viruses inhibits
RIG-I function. We, therefore, investigated the expres-
sion of IFNβ and RIG-I as well as NS1 by real-time RT-
PCR in 5'PPP-RNA or CIAP-RNA transfected A549 cells
that were either uninfected or infected with H5N1 virus
at an MOI of 0.1 for 24 hr following transfection. As
shown in Figure 3C(i&ii), 5'PPP-RNA induced IFNβ and
Figure 2 5'PPP-RNA inhibits replication of 2009 pandemic influ-
enza virus. (A). A459 cells (1 × 106 cells/well) in a 6-well tissue culture 
plate were mock-transfected or transfected with 2 μg of 5'PPP-RNA or 
CIAP-RNA for 24 hr and then infected with A/California/08/09 at an 
MOI of 1.0. Supernatants collected 24 hr post-infection were assayed 
for viral titers as indicated in material and methods. Results shown are 
mean ± SD from three independent experiments and are expressed as 
viral titer (pfu/ml) (B). 5'PPP-RNA also reduced replication of A/Mexico/
4482/09 virus in Balb/c mice. 8 week old female Balb/c mice received 
100 μg of 5'PPP-RNA or PBS alone intravenously for 4 days and the an-
imals were infected with 1000 MID50 of 2009 pandemic virus (A/Mexi-
co/4482/09) on day 1. The lungs were collected on day 4 to determine 
viral titers *P < 0.05 (n = 5).
(A)
(B)Ranjan et al. Virology Journal 2010, 7:102
http://www.virologyj.com/content/7/1/102
Page 5 of 11
RIG-I induction remained unchanged in H5N1 infected
A549 cells. H5N1 virus infection induced the expression
of NS1 by 250-300-fold over uninfected A549 cells [Fig-
ure 3(iii)] and did not induce IFNβ and RIG-I and prior
treatment with 5'PPP-RNA significantly inhibited viral
NS1 expression. Similar effects were observed for 1918
infection in A549 cells (data not shown).
Involvement of RIG-I and type 1 interferon in 5'PPP-RNA 
induced antiviral effect
RIG-I activation has been reported to stimulate type 1
interferon expression that induces an antiviral state. To
study the direct role of 5'PPP-RNA induced RIG-I and
type 1 interferon induction we knockdown RIG-I or
IFNαβ-receptor using gene specific siRNA. As shown in
Figure 4A, selective knockdown of RIG-I in A549 cells
failed to induce antiviral effects when treated with 5'PPP-
RNA and infected with A/New York/02/2001. This con-
firms that 5'PPP-RNA mediated antiviral effects require
RIG-I. 5'PPP-RNA treatment also resulted in induced
IFNβ expression. To understand the correlation between
increased IFNβ level and antiviral effect, we knocked
down IFN-α/β-receptors in A549 cells using siRNA, and
treated the cells with 5'PPP-RNA followed by infection
with A/New York/02/2001. As shown in Figure 4A,
knocking down IFNα/β-receptors significantly abrogated
the antiviral effect of 5'PPP-RNA as compared to control
siRNA knockdown. Furthermore, 5'PPP-RNA treatment
of A549 cells with IFN-α/β-receptors knockdown failed
to induce the expression of RIG-I and IFNβ as assessed by
Figure 3 5'PPP-RNA induced RIG-I and IFNβ expression in A549 cells. (A) A549 (1 × 106 cells/well) in a 6-well tissue culture plate were mock-trans-
fected (control) or transfected with 2 μg of 5'PPP-RNA, CIAP-RNA or chemically synthesized OH-RNA using lipofectamine 2000. After 24 hr of treatment, 
(i) IFNβ and (ii) RIG-I mRNA expression was analyzed by real-time RT-PCR. All data were normalized to β-actin, a house keeping gene and expressed as 
fold increase. Data shown represent the mean ± SD of three independent experiments. (B), (i) A549 cells were transfected with 2 μg of 5'PPP-RNA for 
the indicated times, and RIG-I expression was analyzed by immunoblot. (ii) A549 cells were mock-transfected or transfected with 2 μg of 5'PPP-RNA, 
CIAP-RNA or chemically synthesized OH-RNA for 24 hr. RIG-I expression was analyzed by immunoblot. (iii) A549 cells grown on cover-slips were mock-
transfected or transfected with 2 μg of 5'PPP-RNA or CIAP-RNA for 24 hr. Cells were then paraformaldehyde fixed and immunostained with anti-RIG-I 
antibodies. Alexa fluor 594 goat anti-rabbit IgG Antibody (red fluorescence) or Alexa 488 (green fluorescence) were used as secondary antibodies. Nu-
clei were stained with Hoechst (blue fluorescence). (C) RNA was isolated from A549 cells mock transfected or trasfected with 5'PPP-RNA or CIAP-RNA 
for 24 hr and then infected with wild-type H5N1 virus for 24 hr (as described in Figure legend 1). Real-time RT-PCR was performed to analyze the ex-
pression of (i) IFNβ, (ii) RIG-I and (iii) NS1. All data were normalized to β-actin, a house keeping gene and expressed as fold increase. Data shown rep-
resent the mean ± SD of three independent experiments.
(A)
(B)
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quantitative RT-PCR (Figure 4B). We also measured
IFNβ, RIG-I and NS1 expression by qRTPCR and western
blot analyses for all the viruses used in our studies. H5N1
and H1N1 viruses behaved the same way RIG-I or αβ
IFN-receptor gene knock-down experiments (data not
shown) as A/New York/02/2001 virus. These data clearly
indicate that type 1 interferon is not only required for
antiviral effect but also for upregulating RIG-I expression
by autocrine and paracrine manner.
In vitro therapeutic potential of 5'PPP-RNA
We also investigated the therapeutic potential of 5'PPP-
RNA in A549 cells infected with seasonal influenza virus
A/New York/02/2001 and its oseltamivir-resistant H274Y
mutant. As shown in Figure 5, A549 cells were first
infected with/New York/02/2001 (i) or its oseltamivir-
resistant counterpart H274Y (ii). 5'PPP-RNA trasfection
was carried out post 0 hr, 4 hr and 8 hr infection. Data
suggest that 5'PPP-RNA treatment inhibited both wild-
type and drug-resistant virus replication when delivered
up to 4 hr post infection (p < 0.05), whereas a weaker
inhibitory effect was observed after 8 hr post-infection.
We also investigated the IFNβ and RIG-I expression in
these experiments. As shown in Figure 5(iii&vi), 5'PPP-
RNA transfection post 8 hr A/New York/02/2001 infec-
tion induced significantly low level of IFNβ (iii) and RIG-I
(iv) as compared to those of 0 hr or 4 hr transfection.
Similar results were observed for oseltamivir-resistant
H274Y mutant (data not shown). A time-kinetics studies
of NS1 expression following virus infection suggest that
expression of NS1 reaches optimal by 8 hr of infection
(data not shown). This correlates with diminished antivi-
ral effect of 5'PPP-RNA and down-regulation of type I
interferon and RIG-I level at 8 hr of infection suggesting
NS1 interferes with RIG-I activation.
Discussion
Three influenza pandemics occurred during the 20th
century, with varying degrees of severity; outcomes
ranged from the high levels of illness and death observed
during the 1918 Spanish flu pandemic (estimates of
deaths range from 20 to 100 million) to the much lower
levels observed during the pandemics of 1957 and 1968
Figure 4 Indispensible role of type I interferon in RIG-I-dependent 5'PPP-RNA-induced antiviral effects. (A). A549 cells (1 × 106/well) in a 6-well 
plate were transfected with control siRNA or siRNA against RIG-I or IFN αβ receptors using DharmaFect 1 transfection reagent as per manufacturer 
instructions (Dharmacon, Lafayette, CO, USA). After 24 hr, cells were transfected with 2 μg of 5'PPP-RNA. A549 cells were then infected with A/New 
York/02/2001, a H1N1 virus at 0.1 MOI. Supernatants collected after 24 hr were analyzed for virus growth by plaque assay using MDCK cells. (B) A549 
cells from experiment (A) were also analyzed for IFNβ and RIG-I expression by quantitative RT-PCR as described elsewhere. Data shown represent the 
mean ± SD of three independent experiments.
(A) (B)Ranjan et al. Virology Journal 2010, 7:102
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(approximately one million deaths each) [54,55]. Further-
more, the spread of highly pathogenic avian influenza
viruses since 2004 has also intensified concern over the
emergence of novel strains of influenza with pandemic
potential as exemplified by the current pandemic caused
by a triple reassortant virus [9]. Since the vaccine was not
available for use in the first wave of a pandemic, Oselta-
mivir, a neuraminidase inhibitor became the first choice
for prophylactic and therapeutic intervention. The ongo-
ing emergence of seasonal avian H5N1 as well as novel
H1N1 pandemic influenza viruses that are resistant to
one or other class of antiviral drugs underscores the fra-
gility of the public health strategy to control seasonal
influenza infections [28,56,57]. To overcome these chal-
lenges and improve preparedness against infections with
oseltamivir-resistant viruses, developing novel antiviral
prophylactic as well as therapeutic approaches that offer a
broad spectrum approach and are independent of the
genetic makeup of influenza viruses is absolutely critical.
In the present study, we explored the role of in vitro
transcribed 5'PPP-RNA, a ligand for cytoplasmic RNA
sensor, RIG-I, in antiviral innate immune response
against a panel of influenza viruses including drug-resis-
tant, potential pandemic as well as pandemic strains in
human lung epithelial cells. The broad-spectrum prophy-
lactic potential of 5'PPP-RNA against influenza viruses is
clearly evident from our studies. 5'PPP-RNA significantly
inhibited in vitro growth of not only wild-type drug-sen-
sitive and resistant H5N1 strains with comparable effi-
cacy but also highly pathogenic 1918 pandemic strain.
We also included 2009 pandemic H1N1 viruses in our
studies to see the effect of 5'PPP-RNA both in vitro and in
vivo. Data shown Figure 2A clearly indicate that in vitro
suppression level of A/California/08/09 was similar to
that of other viruses used in this study. Furthermore,
5'PPP-RNA also inhibited A/California/08/09 viral repli-
cation in vivo in Balb/c mice. These data suggest that irre-
spective of type or subtypes, drug-susceptibility status, or
in vivo virulence, the replication of influenza viruses was
inhibited by 5'PPP-RNA. The dose and frequency of
administration of 5'PPP-RNA may influence the extent of
inhibition of viral replication.
Treatment with 5'PPP-RNA not only induced the
expression of IFN-I but also upregulated RIG-I expres-
sion. 5'PPP-RNA induced expression of IFN-I and RIG-I
was not affected by subsequent infection with H5N1 (Fig-
ure 3C) or 1918 pandemic influenza viruses (data not
shown). Induction of these molecular regulators of innate
immune pathway may be involved in the sustained action
of the 5'PPP-RNA-induced antiviral effect.
Viruses have acquired mechanism(s) to escape host
immune surveillance by inhibiting IFN induction path-
ways. The NS1 protein of Influenza A virus inhibits host
antiviral defenses by direct interaction with RIG-I [41-
44]. 5'PPP-RNA treated A549 cells infected with H5N1
virus showed significant reduction of NS1 mRNA expres-
sion as compared to controls, thereby limiting the ability
of the virus to interfere with the host innate immune sys-
tem. RIG-I-mediated antiviral effect by 5'PPP-RNA lasted
for 48 hr which also correlates with sustained induction
of IFN-I that lasted more than 48 hr as revealed by time-
kinetics studies (data not shown). To test the role of RIG-
I, we knocked down RIG-I expression using siRNA,
which abrogated 5'PPP-RNA ability to induce IFNβ and
to inhibit virus replication. Since, there is a significant
increase in IFNβ in addition to RIG-I in 5'PPP-RNA
treated lung epithelial cells, we investigated whether this
effect is due to the action of IFN-I induced by initial
interaction of 5'PPP-RNA with RIG-I. We abrogated the
expression of IFNα/β-receptors of A549 cells using
siRNA and infected them subsequently with A/New
York/02/2001 virus. By knocking down the expression of
IFNα/β receptors, we were unable to detect significant
level of IFNβ and RIG-I induction following 5'PPP-RNA
treatment and inhibitory effect on virus growth (Figure
4A&4B). These findings suggest the direct involvement of
RIG-I-induced type I IFN in the 5'PPP-RNA mediated
antiviral effect. Our data support the previous findings
that IFN can act in an autocrine or paracrine manner to
induce its own expression as well as other antiviral modu-
lators to generate an antiviral state [58]. Though type I
interferon seems to be key player in antiviral action, sys-
Figure 5 Therapeutic potential of 5'PPP-RNA. A459 cells (1 × 106 
cells/well) in a 6-well tissue culture plate were infected with (i) wild-
type A/New York/02/2001 and its (ii) H274Y oseltamivir-resistant A/
New York/02/2001 variant for the 0 hr, 4 hr or 8 hr before treatment 
with 5'PPP-RNA or CIAP-RNA. Supernatants collected after 24 hr of in-
fection were assayed for viral titers as indicated in material and meth-
ods. Cells were harvested to assay IFNβ (iii) and RIG-I (iv) mRNA level by 
Real time RT-PCR. Results shown are mean ± SD from three indepen-
dent experiments and are expressed as viral titer (pfu/ml) or fold in-
crease over controls.Ranjan et al. Virology Journal 2010, 7:102
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temic or local delivery of IFNβ may be toxic and may
result in uncontrolled inflammation [59]. Activation
i n d u c e d  t ype  I  i n t e r f e r o n  i s  s e l f - r e g u l a t e d  b y  f e ed b a c k
mechanisms and prevents side effects.
To evaluate the therapeutic potential of 5'PPP-RNA, we
treated pre-infected (with wild-type and drug-resistant
A/New York/02/2001) A549 cells with 5'PPP-RNA at dif-
ferent time-points. We observed relatively weak antiviral
effect of 5'PPP-RNA, when A549 cells were transfected
with 5'PPP-RNA post 8 hr infection. Interestingly, at this
time point we also observed significantly low RIG-I and
IFNβ expression (Figure 5). These data again suggest the
critical role of RIG-I and type I IFN expression which
may have been suppressed due to NS1 expression at 8 hr
post-infection.
Conclusions
The findings described herein demonstrate that under-
standing host innate immune functions at the molecular
level is a most promising strategy to identify targets, such
as RIG-I for developing newer classes of drugs. These
novel approaches that boost host antiviral innate immune
defenses are broad spectrum in nature, rather than virus-
specific as they inhibited replication of wild-type and
drug-resistant strains of seasonal and avian viruses as
well as pandemic influenza viruses. Since these
approaches are based on stimulating host antiviral
defenses, the possibility of viruses developing resistance
to this approach is remote as these defenses are evolu-
tionarily conserved.
Methods
In vitro synthesis of 5'PPP-RNA
5'PPP-RNAs were synthesized using T7 RNA poly-
merase. Using annealed complimentary oligo nucle-
otides, a DNA template was constructed that contains a
T7 RNA polymerase promoter followed by the sequence
of interest (AGCUUAACCUGUCCUUCAA) to be tran-
scribed [60,61]. Twenty pmol of the DNA template were
incubated with 25U T7 RNA polymerase, 40U RNase
inhibitor in a buffer containing 40 mM Tris-Hcl (pH 8.0),
10 mM DTT, 2 mM spermidine-HCl, 20 mM MgCl2 and
NTPs. DNA template was digested with DNase I and
RNA was purified using phenol:chloroform extraction
and ethanol precipitation. Size, integrity and single
strandness of RNA was analyzed by RNase A digestion
followed by gel electrophoresis. Calf intestine alkaline
phosphatase (CIAP) treatment was performed to remove
tri-phosphate groups from in vitro synthesized RNA.
Briefly, 100 μg of in vitro transcribed RNA was treated
with 150U of CIAP for 3 hr at 37°C in a buffer containing
50 mM Tris-HCl (pH 8.0), 0.1 mM EDTA and 50U of
RNase inhibitor. RNA was purified as described above.
Chemically synthesized RNA with same sequence and
length that contains an OH-group at its 5'-end was pur-
chased from Dharmacon (Lafayette, CO, USA).
T7 polymerase driven in vitro transcribed 5'-PPP-RNA
has been shown to contain dsRNA as well that activates
RIG-I [46,48]. To investigate if our in vitro transcribe
5'PPP-RNA is single stranded RNA (ssRNA) and/or dou-
ble stranded RNA,(dsRNA) we used RNase A treatment
under the conditions that degrades ssRNA, but not
dsRNA. This confirmed that in vitro transcribed RNA
used in our study was RNA only (Additional file 3, Figure
S3).
Cell lines
A549 cells were grown in DMEM (Life Technologies,
Grand Island, NY) supplemented with 10% fetal bovine
serum (FBS), 100? U/ml penicillin and 100 μg/ml strepto-
mycin. Normal human bronchial epithelial (NHBE) cells
(Base, Lonza, Switzerland) were maintained under the
conditions and media specified by the supplier.
Influenza viruses
Seasonal viruses used in this study include the laboratory
H1N1 strain A/Puerto Rico/8/34, wild-type H1N1 (A/
Texas/36/91 and its oseltamivir-resistant variant H274Y;
wild-type A/New York/02/2001 and its H274Y oseltami-
vir-resistant variant), H3N2 (adamantane-resistant A/
Wisconsin/06/94, A30V and A/Wisconsin/12/90, L26F),
and B viruses (wild-type B/Memphis/20/96 and its
R152K mutant resistant to NA inhibitors zanamivir and
oseltamivir), HPAI H5N1 viruses (zanamivir- and oselta-
mivir-sensitive and adamantane-resistant A/Vietnam/
1203/2004 and, adamantane- and oseltamivir-resistant
virus variants A/Vietnam/30408/2005 (H274Y), and A/
Vietnam/HN30408/2005 (N294S),, 2009 pandemic H1N1
viruses, A/California/08/09 and A/Mexico/4482/09, and
the reconstructed 1918 Spanish influenza pandemic virus
(H1N1) generated by plasmid-based reverse genetics
[62]. All human and avian wild-type and drug-resistant
viruses were obtained from the influenza division CDC
repository.
5'PPP-RNA treatment and influenza viral infections
Cells were transfected with 2 μg of in vitro transcribed
5'PPP-RNA, chemically synthesized RNA or CIAP-
treated RNA using Lipofectamine 2000. This dose was
determined by dose-kinetics studies using 1, 2, 4 and 6 μg
of RNA. After 24 hr, cells were infected with the different
viruses used in this study in a 6-well plate. Unless speci-
fied, infection of cells was performed at a multiplicity of
infection (MOI) of 0.1 with or without trypsin supple-
ment. Each treatment was carried out in duplicate cul-
tures. After 24 hr, cells were harvested for RNA and
protein analysis and cell-culture supernatants were col-
lected and stored at -80°C for determination of viral titer
by plaque assay as described previously using MDCKRanjan et al. Virology Journal 2010, 7:102
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cells[41]. This time-point was determined by kinetics
studies using PR8. To study the therapeutic potential of
5'PPP-RNA cells were infected with viruses first for 2, 4
or 8 hr followed by transfection with 5'PPP-RNA. Three
independent experiments were performed at different
times with each treatment carried out in duplicate cul-
tures.
Real Time RT-PCR
Total RNA was isolated from cells using the RNAeasy kit
(Qiagen, Valencia, CA, USA) and real time RT-PCR was
conducted using a Stratagene Q3005 PCR machine for
mRNA expression of RIG-I, IFNβ, NS1, and β-actin. For
each sample, 2 μg of RNA was reverse transcribed using
Superscript II Reverse Transcriptase (Invitrogen, Carls-
bad, CA, USA) according to the manufacturer's direc-
tions. Parallel reactions without reverse transcriptase
were included as negative controls. Reverse transcription
reactions (1/50th of each reaction) were analyzed in using
syber green Q-PCR reagents (Stratagene, La Jolla, CA,
USA). PCR condition was kept as 94°C for 15 s, annealing
at 56°C for 30 s, and extension at 72°C for 30 s for a total
of 45 cycles. The threshold cycle number for cDNA was
normalized to that of β-actin mRNA, and the resulting
value was converted to a linear scale. Data from three
independent experiments were taken account for analy-
s i s.  A l l  d a t a  p o i n ts  f e l l  i n t o  a  n o r m a l  d i s t r i b u t i o n  a n d
there were no outliers.
Primer sets used for these studies are as follows:
IFNβ: forward 5'- TGG GAG GCT TGA ATA CTG CCT
CAA -3'
reverse 5'- TCT CAT AGA TGG TCA ATG CGG CGT
-3'
RIG-I: forward 5'- AAA CCA GAG GCA GAG GAA
GAG CAA -3'
reverse 5'- TCG TCC CAT GTC TGA AGG CGT AAA
-3'
NS1: forward 5'-AGA AAG TGG CAG GCC CTC TTT
GTA-3'
reverse 5'-TGT CCT GGA AGA GAA GGC AAT GGT
-3'
β-actin: forward 5'- ACC AAC TGG GAC GAC ATG
GAG AAA -3'
reverse 5'- TAG CAC AGC CTG GAT AGC AAC GTA
-3'
Immunoblotting
Cells were washed with chilled PBS and then lysed in 100
μl of ice-cold lysis buffer (50 mM Tris-Cl, pH 8.0, 150
mM NaCl, 10% v/v glycerol, 1% v/v Triton X-100, 2 mM
EDTA, 1 mM PMSF, 20 μM leupeptin containing aproti-
nin 0.15 μg/ml) for 20 minutes at 4°C. The protein con-
tent of different samples was determined using a protein
assay reagent (BioRad, Inc., CA, USA). Equal quantities of
solubilized protein were resolved by 10% SDS-PAGE,
blotted to nitrocellulose membrane and probed with the
indicated primary antibodies. Anti-RIG-I was purchased
from Axxora, LLC (San Diego, CA, USA). Anti-β-actin
antibody was purchased from Sigma, St. Louis, MO,
USA. Antibody signals were detected by chemilumines-
cence using secondary antibodies conjugated to horse-
radish peroxidase and an ECL detection kit (Amersham
Biosciences, Inc., NJ, USA).
Fluorescence microscopy
A549 cells grown on cover-slips were mock-transfected
or transfected with 2 μg of 5'PPP-RNA or CIAP-RNA for
24 hr. Cell monolayers were then washed with cold PBS
and fixed with 2% paraformaldehyde for 15 min at room
t e m p e r a t u r e .  C e l l s  w e r e  p e r m e a b l i z e d  w i t h  0 . 0 5 %
saponin in PBS for 30 min at room temperature, and then
blocked with blocking buffer (1% BSA, 5% normal goat
serum and 0.05% saponin in PBS) at room temperature.
Cells were incubated with primary antibodies (1 μg/ml) at
4°C overnight, and were washed 3 times with wash buffer
(0.05% saponin in PBS). Cell monolayers were further
incubated with secondary antibodies (Alexa 594 or 488)
in blocking buffer for 1 hr at room temperature followed
by three washes with buffer. To stain nuclei, cells were
incubated with Hoechst dye (5 μM in PBS containing
0.05% saponin). Cells were further washed (3 times) with
PBS, and were mounted on slides using Prolong antifade
mounting media (Invitrogen, Carlsbad, CA, USA) and
were observed under a Zeiss LSM 510 fluorescence
microscope.
In vivo studies
Female Balb/c mice 6-12 weeks old purchased from Jack-
son Laboratories were intravenously injected 100 μg of
5'PPP-RNA, capped 5'-RNA or PBS complexed with in
vivo-jetPEI according to manufacturer's protocol (Poly-
plus-transfection Inc, San Diego, CA USA) in a volume of
200 μl for 4 days. On day 1, mice were challenged intrana-
saly with 1000 MID50 of 2009 pandemic virus (A/Mexico/
4482/09). A separate group of animals that received only
5'PPP-RNA complexed with in vivo-jetPEI without viral
challenge were observed to determine changes in body
weight and activity. Lungs from control and treated chal-
lenged animals were collected on day 4 to determine viral
titers using MDCK cells as described earlier.
Statistical Methods
To determine the statistical significance among the
5'PPP-RNA or CIAP-RNA treated and untreated groups,
we used Analysis of variance and a value of P < 0.05 was
considered significant. All data points were included in
the analysis and there were no outliers.Ranjan et al. Virology Journal 2010, 7:102
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Additional file 2 Figure S2. Testing viral colonies if they are interferon 
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